降脂药物与银屑病风险的关联:一项孟德尔随机化研究
HMGCR或NPC1L1抑制未发现稳健关联。
要点
- 遗传代理的PCSK9抑制与银屑病风险降低相关,OR 0.69(95%CI 0.55-0.88)。
- FinnGen重复验证PCSK9抑制的OR为0.71(95%CI 0.57-0.88)。
- HMGCR或NPC1L1抑制与银屑病风险无稳健关联。
核心结论
- 该孟德尔随机化研究提示PCSK9参与银屑病发病机制,其抑制与银屑病风险降低相关。
- 这些发现可能为未来研究铺平道路,以实现对银屑病风险人群的降脂药物个体化选择。
研究设计与样本
- 两样本孟德尔随机化研究,于2022年8月至10月进行。
- 纳入UK Biobank和FinnGen中银屑病的全基因组关联研究,以及全球脂质遗传学联盟的低密度脂蛋白数据。
- 采用逆方差加权法,并以多效性稳健方法和共定位作为敏感性分析。
主要发现
- 遗传代理的PCSK9抑制与银屑病风险降低相关(OR 0.69/每降低1个标准差LDL;95%CI 0.55-0.88;P=0.003)。
- FinnGen中重复验证PCSK9抑制的OR为0.71(95%CI 0.57-0.88;P=0.002)。
- 敏感性分析未提供多效性或遗传混杂偏倚的统计学证据。
- HMGCR或NPC1L1抑制未发现稳健关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties. However, large population-level studies are scarce, and causal interpretation of results from traditional observational designs is limited by confounding. OBJECTIVE: To investigate the causal association between genetically proxied lipid-lowering drugs and psoriasis risk. DESIGN, SETTING, AND PARTICIPANTS: This 2-sample mendelian randomization study was performed from August to October 2022 and included population-level genome-wide association studies of psoriasis in the UK Biobank and FinnGen studies and low-density lipoprotein (LDL) by the Global Lipids Genetics Consortium. The inverse variance-weighted method was used with pleiotropy robust methods and colocalization as sensitivity analyses. EXPOSURES: Genetically proxied inhibition of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR, targeted by statins), Niemann-Pick C1-like 1 (NPC1L1, targeted by ezetimibe), and proprotein convertase subtilisin/kexin type 9 (PCSK9, targeted by, eg, alirocumab), using LDL as the biomarker. MAIN OUTCOMES AND MEASURES: Risk of psoriasis. RESULTS: Data from 12 116 patients with psoriasis and approximately 1.3 million individuals with LDL measurement were analyzed. Genetically proxied PCSK9 inhibition was associated with reduced risk of psoriasis (odds ratio, 0.69 per standard deviation reduction in LDL; 95% CI, 0.55-0.88; P = .003), which was replicated in FinnGen (odds ratio, 0.71; 95% CI, 0.57-0.88; P = .002). Sensitivity analyses did not provide statistical evidence of bias from pleiotropy or genetic confounding. No robust association was found for HMGCR or NPC1L1 inhibition. CONCLUSIONS AND RELEVANCE: This mendelian randomization study suggests that PCSK9 is implicated in psoriasis pathogenesis, and its inhibition is associated with reduced psoriasis risk. These findings potentially pave the way for future studies that may allow personalized selection of lipid-lowering drugs for those at risk of psoriasis.
引用
- Zhao SS, Yiu ZZN, Barton A, et al. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. JAMA Dermatol. 2023. PMID: 36696131. doi:10.1001/jamadermatol.2022.6051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。